Abstract 32P
Background
Secondary trastuzumab resistance seriously affects HER2-positive breast cancer treatment. However, we still lack knowledge about changes in tumor cells and their interaction with tumor microenvironment (TME) components during resistance formation. This study aimed to uncover metabolism pathway changes during trastuzumab resistance formation and potential epigenetic variations that are relevant to these processes.
Methods
Induced secondary trastuzumab-resistant SKBR3_HR cell line together with the original trastuzumab-sensitive SKBR3 cell line were applied in this study. Total RNA was collected for transcriptome analysis. Anti-H3K4me3, K27me3 and K27ac antibodies were chosen for CUT&Tag sequencing library preparation. Total genome DNA was prepared for Micro-C sequencing library preparation. Activity score of metabolism pathway was calculated as relative gene expression value averaged over all genes in this pathway in certain cell types. Extracellular prostaglandin E2 (PGE2) was measured by ELISA.
Results
SKBR3_HR cells showed higher trastuzumab tolerance than SKBR3 cells. Upregulation of arachidonic acid metabolism, which was characterized by two overexpressed genes, PTGS1 and PTGES, was observed in SKBR3_HR cells, resulting in PGE2 accumulation in culture medium. Variations of 1519 H3K27me3 peaks and 256 H3K4me3 peaks at promoters were observed during resistance formation. Little H3K27me3 but considerable raised H3K4me3 levels at PTGS1 and PTGES gene promoters may stimulate their transcription.692 altered active enhancers were measured during resistance formation. Meanwhile, 2741 and 7007 DNA loops were lost and gained. New DNA loops formation between PTGS1 gene promoter and enhancers nearby, indicating a positive synergy regulatory on PTGS1 gene expression together with promoter modifications.
Conclusions
During trastuzumab resistance formation, promoter H3K4me3, active enhancers and DNA loops together regulate PTGS1 and PTGES expression, activate arachidonic acid metabolism, and eventually stimulate PGE2 accumulation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (81972484), National Natural Science Foundation of China (82203488).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
36P - Molecular assessment of clinical antitumour therapeutics utilising established pancreatic ductal adenocarcinoma patient-derived models
Presenter: Young-Ah Suh
Session: Poster session 09
37P - Nischarin can be a target for stromal normalisation in pancreatic ductal adenocarcinoma
Presenter: Jelena Grahovac
Session: Poster session 09
38P - Effects of antiemetics on zolbetuximab-induced gastric injury and emesis frequency in ferrets
Presenter: Jane Weng
Session: Poster session 09
39P - Casein kinase 2 modulates epithelial–mesenchymal transition through helicobacter pylori CagA-dependent pathway in gastric cancer cells
Presenter: SODAM LEE
Session: Poster session 09
40P - Bioinformatic evaluation of the transcriptomic and immunologic profile of prostate tumors with high expression of kallikrein-2
Presenter: Irene Moreno
Session: Poster session 09
42P - Developing a photodynamic therapy strategy targeted to endometrial cancer stem cells
Presenter: Beatriz Serambeque
Session: Poster session 09
43P - Looking for therapeutic targets on the proteome profile of endometrial cancer stem cells
Presenter: Mafalda Laranjo
Session: Poster session 09
44P - PAUF as a target for treatment of high PAUF-expressing ovarian cancer
Presenter: Junghyun Cho
Session: Poster session 09
45P - Therapeutic potential of ISM8207: A novel QPCTL inhibitor, in triple-negative breast cancer and B-cell non-Hodgkin lymphoma
Presenter: Sujata Rao
Session: Poster session 09